Abstract Library

#3984 The contribution of functional imaging in predicting the risk of recurrence after pancreatic surgery for neuroendocrine tumors

Introduction: Pancreatic neuroendocrine tumors (pNETs) are rare and heterogeneous, comprising 1 to 3% of all pancreatic neoplasms. The recurrence rate of non-metastatic pNETs varies, reaching up to 50% depending on the series, highlighting the difficulty in selecting candidates for surgery. However, there is no published data regarding the prognostic value of functional PET imaging combined with clinical and pathological characteristics.

Conference:

Presenting Author:

Authors: Pencréac'h S, de Mestier L, Fuks D, Paye F, de Ponthaud C,

Keywords: pNET, PET-68Ga-DOTATOC, recurrence, pancreatic surgery,

#3221 Independent administration of long-acting somatostatin analogues (SSAs) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET): Potential savings of increased uptake in the UK National Health Service (NHS)

Introduction: Lanreotide Autogel (LAN) and octreotide long-acting release (OCT) are long-acting SSAs used to treat GEP-NET. Only LAN is approved for independent (self/partner) injection, obviating need for in-person provider visits. Uptake of this option, already convenient for some patients, has accelerated in the UK amid the COVID-19 pandemic, with delivery modes reorganized in line with “COVID-19 rapid guideline: delivery of systemic anticancer treatments [NG161]” published for the NHS.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Harrow B, Cristeau O, Clay E, Francois C, Frankcom I,

Keywords: somatostatin analogues, GEP-NET, HEOR, covid-19,

#3124 Surgery for Zollinger-Ellison syndrome in Multiple Endocrine Neoplasia Type 1 - A AFCE and GTE cohort study (Association Francophone de Chirurgie Endocrinienne et Groupe d’Etude des Tumeurs Endocrines)

Introduction: Management of ZES in MEN1 remains controversial, and little is known about the current surgical strategies and outcomes.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Goudet P

Authors: Goudet P, Gaujoux S, Pattou F, Carnaille B, Cardot-Bauters C,

Keywords: MEN1, surgery, metastasis,

#3114 Burden associated with Multiple Endocrine Neoplasia type 1 (MEN1)

Introduction: Natural history and especially overall risk of death compared to the general population of multiple endocrine neoplasia type 1 (MEN1) patients is poorly known.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Gaujoux S

Authors: Gaujoux S, Martin G, Mirallié E, Pattou F, Carnaille B,

Keywords: multiple endocrine neoplasia, men1, survival, surgery, natural history,

#2956 Somatostatin Analogs: The Economic Value of Lanreotide Autogel Delivery Attributes in the Treatment of GEP-NET versus Octreotide LAR – A UK Budget Impact Analysis

Introduction: Lanreotide autogel (LAN) and octreotide long acting release (OCT) are long-acting somatostatin analogues (LA-SSAs) used to treat patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). However, the treatments differ in terms of injection route, need for administration by a health care professional and dosing interval.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Feuilly M

Authors: Feuilly M, Cristeau O, Clay E, François C, Whalen J,

Keywords: somatostatin analogues, economics,